Survodutide Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Survodutide Does & How It Works

What It Does - Functional Outcomes

• Reduces body weight substantially through simultaneous appetite suppression and increased resting energy expenditure
• Lowers blood glucose and HbA1c in people with type 2 diabetes through glucose-dependent insulin stimulation
• Clears fat from the liver and reduces liver fibrosis in metabolic liver disease (MASH/MASLD)
• Improves cardiometabolic risk markers including blood pressure, waist circumference, and VLDL cholesterol
• Delays gastric emptying, reducing postprandial glucose spikes and prolonging satiety
• Increases thermogenesis (the rate at which the body burns calories at rest) through glucagon receptor activation

How It Works - Mechanism of Action

GLP-1 Receptor Agonism: Appetite and Glycemic Control (Evidence: Human clinical trial data - multiple Phase 2 RCTs)

Survodutide binds the GLP-1 receptor, a protein found on cells in the pancreas, gut, and brain. This triggers downstream signals that suppress appetite through hypothalamic and hindbrain pathways, stimulate insulin secretion in proportion to glucose levels, and slow the rate at which the stomach empties. The in vitro receptor binding ratio is approximately 8:1 favoring GLP-1R over glucagon receptor (GCGR). That means GLP-1 effects dominate at therapeutic doses by design.

Glucagon Receptor Agonism: Thermogenesis and Liver Fat Clearance (Evidence: Preclinical mechanistic data; human Phase 2 data for downstream outcomes)

Activation of the glucagon receptor (GCGR) produces a distinct set of metabolic effects that GLP-1-only drugs do not have. GCGR stimulation increases basal metabolic rate through thermogenesis, raising cellular energy expenditure independently of food intake changes. Critically, this thermogenic effect occurs without activating the sympathetic nervous system. That means it does not carry the cardiovascular risks (elevated heart rate, blood pressure spikes, arrhythmia) associated with stimulant-class thermogenic compounds. In liver and adipose tissue, GCGR activation drives lipolysis, directly breaking down stored fat in hepatic tissue.

Counterbalanced Dual-Receptor Design: Solving the Hyperglycemia Problem (Evidence: Human clinical data - Phase 2 T2D trial)

Pure glucagon receptor stimulation raises blood sugar by triggering hepatic glucose release. That is why isolated GCGR agonism has never been a viable therapeutic strategy on its own. Survodutide's engineering solution is to pair GCGR activity with dominant GLP-1R activity at a ratio of approximately 1:8. At therapeutic doses, the insulin-stimulating effects from GLP-1R activation consistently outweigh the glucose-elevating effects from GCGR activation. The Phase 2 T2D trial confirmed this counterbalance works in human subjects: dose-dependent HbA1c reductions were achieved without uncontrolled hyperglycemia.

Oxyntomodulin Analog Design (Evidence: Pharmacological/structural characterization)

Survodutide is structurally derived from a glucagon backbone with incorporated GLP-1 receptor-binding residues. Its natural analog is oxyntomodulin, an endogenous hormone produced in the gut that activates both GLP-1R and GCGR naturally. The problem with endogenous oxyntomodulin is that it is cleared from the bloodstream within minutes. Survodutide replicates oxyntomodulin's dual-receptor pharmacology using a peptide backbone modified with an acylated fatty acid chain. That modification creates depot-like behavior in subcutaneous tissue, sustaining plasma levels long enough for once-weekly dosing.

Survodutide Molecular Profile

Structure reference: Survodutide (BI 456906) is an investigational compound whose full structural data is not yet deposited in PubChem or equivalent open databases as of July 2026. See Boehringer Ingelheim patent filings and Zealand Pharma licensing documentation for available structural data.

Survodutide Uses & Benefits

Obesity and Overweight

Obesity and overweight with metabolic complications are the primary indications driving survodutide's clinical development. Phase 2 trial data across 386 adults with BMI at or above 27 without diabetes demonstrated clear dose-dependent weight loss. The highest studied dose produced -14.9% mean body weight reduction versus -2.8% for placebo at 46 weeks, extending to approximately -18.7% in maintenance phase analyses. The dual-pathway mechanism addresses weight through both caloric intake reduction (GLP-1R) and resting energy expenditure increase (GCGR). Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials are currently evaluating survodutide in larger, longer-duration populations. (Evidence: Strong - Phase 2 human RCT, NCT04667377)

Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis

MASH (formerly called NASH) is a condition in which fat accumulation in the liver triggers inflammation and progressive scarring (fibrosis) that can eventually progress to cirrhosis. Survodutide's dual-pathway hepatic mechanism makes it uniquely suited to this indication: GCGR activation drives direct lipolysis in liver tissue, while GLP-1R-mediated weight reduction reduces ongoing lipid delivery to the liver. Phase 2 biopsy-confirmed data in patients with F2 and F3 fibrosis showed 64.5% achieving fibrosis improvement without MASH worsening versus 38.6% on placebo, and 57-67% achieving at least 30% liver fat reduction versus 14% on placebo. These results supported initiation of the Phase 3 LIVERAGE trial enrolling approximately 1,800 patients with planned 7-year follow-up. (Evidence: Strong - biopsy-confirmed Phase 2 human RCT, NCT05243327)

Type 2 Diabetes

Survodutide is being studied in type 2 diabetes both as a standalone glycemic agent and as a combined weight-and-glucose management therapy. The theoretical complexity (GCGR activation raises blood sugar, GLP-1R activation lowers it) was tested and resolved in a 16-week Phase 2 dose-response trial. That trial showed dose-dependent HbA1c reductions of up to -1.71% absolute at the highest doses, without evidence of uncontrolled hyperglycemia. Body weight reductions occurred concurrently with glycemic improvements. Phase 3 SYNCHRONIZE-2 is specifically designed around the T2D-with-obesity population, with co-primary endpoints of body weight and HbA1c reduction over 76 weeks. (Evidence: Moderate - Phase 2 human dose-response trial, 16-week duration)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Including Cirrhosis

Beyond MASH with active inflammation, survodutide has been studied in the broader MASLD spectrum including compensated and decompensated cirrhosis. A Phase 1 trial (NCT05296733) enrolled patients across Child-Pugh A, B, and C cirrhosis severity classifications. It found that even in severe cirrhosis, survodutide's pharmacokinetics were not significantly altered, meaning the damaged liver did not change how the compound behaves in the body. Exploratory efficacy signals in this Phase 1 setting included liver fat reduction, fibrosis biomarker improvements, and body weight reduction even in the cirrhotic population. This finding has direct clinical significance because cirrhosis patients are a primary treatment target, and concern about pharmacokinetic alterations in liver disease is otherwise a limiting factor with many compounds. (Evidence: Preliminary - Phase 1 safety/pharmacokinetic primary; efficacy signals exploratory)

Cardiometabolic Risk Reduction

Cardiovascular risk reduction is a secondary outcome in Phase 2 obesity trials and the specific focus of the Phase 3 SYNCHRONIZE-CVOT enrolling 4,935 participants. Phase 2 data demonstrated improvements in systolic and diastolic blood pressure, waist circumference, and VLDL cholesterol (all established cardiovascular risk biomarkers) in treated participants versus placebo. Whether these surrogate endpoint improvements translate to fewer actual cardiovascular events is precisely what the CVOT is designed to determine, and results are not yet available. (Evidence: Preliminary for hard cardiovascular outcomes - Phase 3 CVOT ongoing; Moderate for surrogate endpoints from Phase 2 RCT data)

Where This Guide Comes From

Survodutide Results & Timelines

Because survodutide is an investigational compound with no established real-world user base outside of clinical trials, the outcome timelines below are drawn from Phase 2 clinical trial data rather than from community protocol tracking. This is an important distinction from most other entries in the MPP library. There is no meaningful community of self-experimenting users with documented logs for this survodutide peptide. The timelines reflect what clinical trial participants experienced, organized by the indication being measured.

Obesity and Weight Reduction

• Weeks 1-6: The early dose escalation period. Most trial participants in Phase 2 experienced the GI adaptation phase during these weeks. Nausea, reduced appetite, and vomiting peaked here before stabilizing. Measurable weight loss begins, but the GI adjustment period dominates subjective experience for many participants.
• Weeks 6-12: As dosing stabilizes post-escalation, appetite suppression becomes the dominant reported effect. Weight loss becomes clearly measurable in this window. Phase 2 trial data shows consistent downward weight trends from this point onward across all active dose arms.
• Weeks 12-24: Progressive weight reduction continues. The dose-response relationship is clear: higher doses produce greater and faster weight loss during this period.
• Weeks 24-46: The 4.8 mg/week arm reached -14.9% mean body weight reduction by week 46. Maintenance phase analyses suggest continued reduction toward approximately -18.7% at the highest effective doses for participants who remain in the protocol.

MASH and Liver Outcomes

• Weeks 1-12: Liver fat reduction, measured by imaging, begins accumulating during this period. Blood-based liver enzyme markers may show early improvement.
• Weeks 12-24: Continued liver fat reduction. Imaging-assessed changes become more pronounced with sustained treatment.
• Week 48: The Phase 2 MASH trial measured histologic outcomes at 48 weeks via paired biopsies. This is the first timepoint at which structural fibrosis improvement was documented: 64.5% of treated patients versus 38.6% of placebo achieved the fibrosis improvement plus no MASH worsening composite endpoint.
• Beyond 48 weeks: The Phase 3 LIVERAGE trial has planned 7-year follow-up to capture longer-term outcomes including cirrhosis progression and clinical events. Long-term liver data beyond one year is not yet available.

Glycemic Outcomes in Type 2 Diabetes

• Weeks 1-8: Early glucose-lowering effects from GLP-1R-mediated insulin stimulation begin accumulating. Postprandial glucose improvements may be noticed earlier than fasting glucose changes.
• Week 16: The Phase 2 T2D trial measured its primary glycemic outcomes at 16 weeks, documenting HbA1c reductions of up to -1.71% absolute at the highest doses. HbA1c is a 3-month rolling average, so improvements at 16 weeks reflect changes beginning from the first weeks of treatment.
• Ongoing: Phase 3 SYNCHRONIZE-2 evaluates glycemic durability over 76 weeks. Long-term HbA1c maintenance data is not yet available.

How to Administer Survodutide

Subcutaneous Injection (SubQ)

Subcutaneous injection is the only documented route for survodutide across all clinical trials and all indications. All Phase 1, Phase 2, and Phase 3 studies have used weekly subcutaneous administration as the standard protocol. The injection is designed for self-administration consistent with other once-weekly GLP-1-class agents, though specific injection site guidance is protocol-dependent and not publicly specified in available trial documentation. The once-weekly interval is pharmacokinetically determined by the acylation modification: the fatty acid chain creates depot-like behavior in subcutaneous tissue that sustains systemic levels throughout the week.

Oral

Oral administration of survodutide is not viable and has not been studied. Like all peptide compounds of this molecular class, survodutide would be degraded by gastric acid and digestive proteases before reaching systemic circulation in any meaningful concentration. The clinical development program has been built entirely around subcutaneous delivery, and no oral formulation has been reported in development.

Survodutide Dosage & Cycle Length

Overall dosing range: 0.6 mg to 6.0 mg per week via subcutaneous injection - range studied across indications in Phase 1 and Phase 2 clinical trials

How the goal shifts where you land:

• Low end of range (0.6-1.2 mg/week): Used in Phase 2 obesity dose-ranging arms; associated with modest but measurable weight reduction (-6.2% at 0.6 mg/week). Likely represents a starting or early escalation dose rather than a therapeutic maintenance target.
• Mid range (2.4 mg/week): Studied across both obesity and MASH trials. Associated with meaningful weight reduction and liver fat clearance. Represents the lower bound of the therapeutically active maintenance range based on Phase 2 data.
• High end of range (4.8-6.0 mg/week): The 4.8 mg/week dose produced the strongest weight loss signal in the Phase 2 obesity trial (-14.9% mean body weight reduction, with up to -18.7% in maintenance phase analyses). The 6.0 mg/week dose was studied specifically in MASH trials. These higher doses are associated with the greatest efficacy but also the highest GI adverse event burden. (Evidence: Strong - Phase 2 human RCT data)

Frequency: Once weekly. The once-weekly interval is not a design preference; it is a pharmacokinetic necessity determined by the acylation modification. The fatty acid chain attached to the peptide backbone extends plasma half-life to support weekly dosing, and all trials have been built around this schedule.

Cycle length: Phase 2 trials ran 46-48 weeks across obesity and MASH indications. Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 are evaluating 76-104 weeks of continuous weekly dosing. Phase 3 LIVERAGE includes planned follow-up extending to approximately 7 years. There is no documented on/off cycling pattern for survodutide. The clinical trial design treats it as a continuous chronic therapy, consistent with how other GLP-1 class agents are used in clinical practice.

Dose escalation: This is a clinically important consideration. Phase 2 trials used a rapid escalation schedule, increasing the dose every two weeks. This rapid escalation schedule was identified as the primary driver of GI adverse events: 75% of treated participants in the Phase 2 obesity trial reported GI events, concentrated heavily in the first six weeks of treatment. Phase 3 SYNCHRONIZE trials use a slower uptitration schedule with provisions for temporary dosing pauses to manage GI tolerability. The expectation is that Phase 3 GI event rates will be lower than Phase 2 as a direct result of the modified escalation approach.

Survodutide Vial Sizes, Costs & Quality

Common vial sizes: Survodutide is not commercially available. It is an investigational compound under active Phase 3 clinical development by Boehringer Ingelheim. As of April 2026, it has not been approved for prescription use and is not sold through research peptide suppliers or pharmacies in the standard sense. Access is currently limited to participation in registered clinical trials (SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and related Phase 2 trials still enrolling).

Market availability note: Research peptide suppliers occasionally list investigational compounds under their development codes or alternate spellings before formal approval. As of the writing of this guide, no established research-grade commercial supply chain exists for survodutide comparable to what exists for approved or widely researched peptides. Anyone encountering survodutide or survodutide offered through informal channels should apply stringent quality scrutiny. The lack of regulatory approval and an established supply chain significantly elevates the sourcing risk for this specific compound.

Typical cost range: Not applicable as a commercial reference. Survodutide is not available at retail. For context, once-weekly subcutaneous GLP-1-class peptides in this molecular weight and dosing range typically cost substantially more per month than simpler peptide compounds when commercially available.

Storage - lyophilized (dry powder):

• Temperature: Refrigerate at 2-8 degrees C; protect from light
• Shelf life: Consistent with other acylated peptides; store per manufacturer specifications once available commercially
• Light sensitivity: Protect from light exposure

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C
• Use window: Clinical trial supply protocols are not publicly available; standard acylated peptide handling protocols suggest use within 28-30 days once reconstituted, but this is class-based guidance rather than compound-specific published data

Normal appearance after reconstitution: Clear to slightly opalescent solution consistent with other acylated peptide therapeutics in this class. Some mild opalescence is normal given the acylation modification and does not indicate degradation.

Signs of degradation: Visible particulates, unexpected discoloration, cloudiness beyond the normal slight opalescence, or any unusual odor. Degraded material should not be used.

Quality Considerations

Survodutide presents a sourcing challenge that is categorically different from most other peptides. Because it is an active Phase 3 pharmaceutical development asset with no approved commercial pathway, there is no legitimate retail supply chain. Any product sold outside a registered clinical trial cannot have been sourced through the Boehringer Ingelheim development program. The synthesis of a 29-amino-acid acylated peptide at research-grade purity is technically demanding and expensive; cutting corners in the acylation chemistry specifically can produce something that looks like the target compound on a basic assay but behaves differently at the receptor level. Without a certified analytical reference standard to test against - something that does not exist in public databases for survodutide - even third-party certificate of analysis testing is limited in what it can confirm. This is not a situation where choosing U.S.-manufactured peptides with third-party testing fully resolves the risk; the risk landscape here is fundamentally more complex than it is for established research peptides with well-characterized supply chains and publicly available reference standards.

Survodutide Side Effects & Safety

Side Effect Spectrum

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC): Standard class contraindication for GLP-1 receptor agonists based on rodent carcinogenicity data; applied to survodutide on the same pharmacological basis. Human relevance is considered low but the precautionary contraindication is standard across this drug class.
• Multiple endocrine neoplasia type 2 (MEN 2): Standard class contraindication for GLP-1 receptor agonists, applied to survodutide on the same basis as MTC risk above.
• Active or recent pancreatitis: Insufficient data to confirm safety; pancreatitis risk associated with the GLP-1 agonist class warrants exclusion pending further safety characterization.
• Decompensated liver disease in the absence of specialized monitoring: Phase 1 cirrhosis data demonstrated preserved pharmacokinetics in Child-Pugh C patients; however, the same data showed drug-related adverse events in 82-88% of patients during multiple-dose treatment. Use in this population outside a monitored trial setting is not established.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data for survodutide specifically; use is not recommended without medical supervision. Weight loss therapy is generally not indicated in pregnancy.
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision.
• Patients using insulin or insulin secretagogues (sulfonylureas): The glucose-dependent insulin-stimulating effect of GLP-1R agonism adds to the insulin load from these medications, increasing hypoglycemia risk. Dose adjustment of concurrent insulin or sulfonylurea therapy may be required.
• History of gastroparesis or severe gastrointestinal dysmotility: GLP-1R-mediated gastric emptying delay would compound pre-existing dysmotility. Survodutide has not been specifically studied in this population.
• Patients with cirrhosis or advanced liver disease: Phase 1 data demonstrates pharmacokinetic preservation, but the high adverse event burden (82-88% drug-related AEs in multiple-dose cohorts) requires careful clinical monitoring in this population.

Red Flags - Stop Use and Seek Medical Attention If:

• Severe or persistent abdominal pain, particularly radiating to the back, which may indicate pancreatitis
• Signs of a serious allergic reaction including rash, difficulty breathing, or swelling of the face or throat
• Symptoms of severe hypoglycemia in patients also using insulin or sulfonylureas: confusion, extreme shakiness, or loss of consciousness
• Sudden, severe changes in vision
• Significant signs of dehydration from persistent vomiting: inability to keep fluids down, extreme weakness, or dark urine

Drug and Compound Interactions

No drug-drug interaction studies specific to survodutide have been published in the available literature as of July 2026. Based on pharmacological class, the most relevant interaction concern involves medications that affect blood glucose, particularly insulin and sulfonylurea-class diabetes drugs. Survodutide's GLP-1R-mediated insulin stimulation adds to the hypoglycemic effect of these agents. Gastric emptying delay from GLP-1R agonism can also affect the absorption rate of orally administered medications; drugs with narrow therapeutic windows and time-sensitive absorption profiles may require monitoring during treatment initiation. Interactions with other GLP-1 agonists or dual and triple receptor agonists are theoretical at present; combining compounds from this class is not studied and is not recommended.

Survodutide Research & Studies

Pharmacokinetics & Metabolism

Survodutide's pharmacokinetic profile is defined by its acylation modification, which extends plasma half-life sufficiently to support once-weekly subcutaneous dosing. The sections below cover what is known from published and available trial data, along with explicit notes on where gaps exist.

Absorption & Bioavailability

Survodutide is administered via subcutaneous injection in all documented research settings. The acylation modification (a fatty acid chain attached to the peptide backbone) creates depot-like behavior in subcutaneous tissue, enabling slow, sustained absorption into systemic circulation. This is the same pharmacokinetic engineering strategy used in semaglutide and other once-weekly GLP-1 class agents. Bioavailability data for subcutaneous administration has not been published in accessible form as of July 2026; bioavailability for acylated peptides of this class via subcutaneous route is generally high relative to other routes.

Distribution

Distribution data specific to survodutide is not published in accessible form. Based on pharmacological class and the compound's receptor targets (GLP-1R and GCGR expressed in pancreas, liver, adipose tissue, brain, and gut), distribution is expected to reach these target tissues. GLP-1 receptor agonists as a class demonstrate central nervous system effects via hypothalamic and hindbrain GLP-1R, indicating CNS access. The degree of blood-brain barrier permeability for survodutide specifically has not been characterized in public literature.

Half-Life

The acylation modification extends the plasma half-life of survodutide to support once-weekly subcutaneous dosing: this is confirmed by the clinical trial design across all studies. Specific half-life measurements have not been published in the publicly accessible literature. For comparison, semaglutide's acylation produces a half-life of approximately 165-184 hours; survodutide's acylation is designed to achieve a comparable weekly-dosing pharmacokinetic profile.

Metabolism & Elimination

Specific metabolism and elimination data for survodutide are not published in accessible form. As a peptide, metabolism is expected to proceed via proteolytic degradation and amino acid recycling pathways. The Phase 1 cirrhosis trial (NCT05296733) demonstrated that severe hepatic impairment across Child-Pugh A, B, and C classifications does not significantly alter survodutide's pharmacokinetics. That means hepatic metabolism or elimination is not rate-limiting, and no dose adjustment appears required based on liver function status alone.

Mechanistic Research

Dual GLP-1R and GCGR Agonism and Weight Reduction (Evidence: Human clinical trial data plus preclinical mechanistic data)

Preclinical mechanistic studies with survodutide demonstrated simultaneous reduction in energy intake and increase in energy expenditure, effects attributable to GLP-1R and GCGR pathways respectively. The critical engineering insight was that GCGR-mediated thermogenesis proceeds without sympathetic nervous system activation, avoiding the cardiovascular risks associated with stimulant-class thermogenic agents. In the Phase 2 obesity trial (NCT04667377), the combination of reduced caloric intake and increased energy expenditure produced weight losses substantially exceeding what GLP-1-only agents typically achieve. The 4.8 mg/week dose arm reached -14.9% mean body weight reduction at 46 weeks.

Counterbalanced Glycemic Mechanism (Evidence: Human clinical data - Phase 2 RCTs)

The pharmacological balance between GCGR-mediated hepatic glucose release and GLP-1R-mediated insulin stimulation is central to survodutide's design and was confirmed in human clinical data. In the Phase 2 T2D trial, dose-dependent HbA1c reductions of up to -1.71% absolute were achieved without evidence of uncontrolled hyperglycemia from glucagon receptor activation. The receptor binding ratio of approximately 1:8 (GCGR:GLP-1R) was specifically engineered to ensure that insulin-stimulating effects dominate over glucose-elevating effects at therapeutic doses.

Hepatic Fat Clearance via Dual-Pathway Mechanism (Evidence: Human biopsy-confirmed Phase 2 data)

GCGR activation in liver and adipose tissue drives lipolysis (the breakdown of stored fat), while GLP-1R-mediated appetite suppression and weight reduction reduce the ongoing delivery of excess lipid substrate to the liver. In the Phase 2 MASH trial (NCT05243327), 57-67% of treated patients achieved at least 30% liver fat reduction compared to 14% on placebo, confirmed by imaging assessment. Histologic assessment via paired liver biopsies confirmed fibrosis improvement of at least one stage in 34-36% of treated patients versus 22% of placebo patients.

Condition-Focused Research

Obesity - Phase 2 Dose-Ranging Trial {#research-obesity}

The primary efficacy trial for survodutide in obesity (NCT04667377) enrolled 386 adults with BMI at or above 27 without diabetes and randomized them to placebo or one of four weekly doses over 46 weeks. The trial demonstrated clear dose-dependent weight loss, with the 4.8 mg/week dose producing -14.9% mean body weight reduction versus -2.8% for placebo. Maintenance phase analyses extended the observed weight loss estimate to approximately -18.7%. Secondary cardiometabolic endpoints including systolic blood pressure, diastolic blood pressure, waist circumference, and VLDL all improved in the active arms relative to placebo. (Evidence: Strong - Phase 2 human RCT)

MASH and Liver Fibrosis - Phase 2 Biopsy Trial {#research-mash}

The Phase 2 MASH trial (NCT05243327) enrolled patients with biopsy-confirmed MASH and fibrosis stage F2 or F3, randomizing them to survodutide (2.4 mg, 4.8 mg, or 6.0 mg per week) or placebo over 48 weeks. Paired liver biopsies at baseline and week 48 provided histologic confirmation of outcomes. Fibrosis improvement of at least one stage was achieved in 34-36% of treated patients versus 22% on placebo. The composite endpoint of fibrosis improvement without MASH worsening reached 64.5% in the treated group versus 38.6% in placebo (p less than 0.001). Liver fat reductions of at least 30% were achieved in 57-67% of treated patients versus 14% on placebo. These results supported initiation of the Phase 3 LIVERAGE trial enrolling approximately 1,800 patients. (Evidence: Strong - biopsy-confirmed Phase 2 human RCT)

Type 2 Diabetes - Phase 2 Dose-Response Trial {#research-t2d}

A 16-week Phase 2 dose-response trial in adults with type 2 diabetes evaluated survodutide across multiple dose levels, demonstrating dose-dependent HbA1c reductions of up to -1.71% absolute at the highest doses alongside dose-dependent body weight reductions. Glycemic control was maintained without evidence of uncontrolled hyperglycemia from the GCGR arm, confirming the theoretical pharmacological balance between the two receptor pathways in a T2D population. The 16-week duration limits conclusions about long-term glycemic durability, which Phase 3 SYNCHRONIZE-2 is designed to address with a 76-week observation window. (Evidence: Moderate-to-Strong - Phase 2 human dose-response data; limited to 16-week duration)

Cirrhosis Safety - Phase 1 Trial {#research-cirrhosis}

The Phase 1 cirrhosis trial (NCT05296733) enrolled adults with compensated and decompensated MASLD-related cirrhosis across Child-Pugh A, B, and C severity classifications. A single 0.3 mg subcutaneous dose demonstrated tolerability across all severity groups. Extended multiple-dose cohorts escalating to 6.0 mg/week over 28 weeks showed drug-related adverse events in 82-88% of patients during active dosing, consistent with GI class effects. No major pharmacokinetic alterations were found compared to healthy individuals. Exploratory efficacy signals included reductions in liver fat, fibrosis biomarkers, and body weight even in the cirrhotic population. Data from this trial was presented at the EASL Congress in June 2024 in Milan. (Evidence: Phase 1 - safety and pharmacokinetic primary; efficacy signals exploratory)

Cardiovascular Outcomes - Phase 3 CVOT {#research-cvot}

The SYNCHRONIZE-CVOT trial (NCT06077864) is a Phase 3 event-driven cardiovascular outcomes trial enrolling 4,935 participants with overweight or obesity plus established cardiovascular disease, chronic kidney disease, or significant cardiovascular risk. The trial is designed to run up to two years and three months, with 21 planned in-person assessment visits, assessing major adverse cardiovascular events (MACE) as the primary outcome. Phase 2 data showed improvements in blood pressure, waist circumference, and VLDL (all established cardiovascular risk biomarkers), but these surrogate endpoints do not substitute for hard outcome data. Results from the CVOT are not yet available and are required for regulatory approval in most major markets. (Evidence: Preliminary for cardiovascular hard outcomes - Phase 3 ongoing, no results yet)

Safety & Tolerability Research

The safety profile of survodutide across Phase 1 and Phase 2 trials is dominated by gastrointestinal adverse events consistent with the GLP-1 receptor agonist pharmacological class. In the Phase 2 obesity trial, 91% of treated participants experienced any adverse event versus 75% on placebo, with GI events accounting for 75% in treated versus 42% in placebo. A pooled analysis of four Phase 2 RCTs quantified risk ratios for specific GI events: nausea (RR 3.30), vomiting (RR 6.64), and dyspepsia (RR 6.93) versus placebo. Treatment discontinuation was approximately 4.5 times more likely with survodutide than placebo in the pooled analysis (RR 4.53, 95% CI 2.15-9.54). The Phase 2 rapid dose escalation schedule was identified as the primary driver of GI event burden; Phase 3 protocols have adopted a slower uptitration schedule with temporary dosing pauses specifically to mitigate this. The Phase 1 cirrhosis trial reported 82-88% drug-related adverse event rates in multiple-dose extended cohorts, consistent with class effects rather than unique hepatic safety signals. No unexpected serious safety signals have emerged from the Phase 2 program.

Research Limitations

Phase 3 results (the definitive efficacy and safety data required for regulatory submissions) are not yet available for any indication. The Phase 2 evidence base, while human and clinical, comes from smaller trials not powered for long-term hard outcomes. The Phase 2 meta-analysis specifically noted that participant demographics have been skewed toward White and female populations, limiting generalizability across demographic groups. The longest published safety observation window is 48 weeks in Phase 2; long-term safety data extending beyond one year is not yet in the public domain. Full pharmacokinetic characterization including half-life and bioavailability data has not been published in accessible literature, limiting independent evaluation of the compound's behavior. No head-to-head comparison trial against other dual-receptor agonists (such as tirzepatide) has been published, and the metabolic rate comparison trial against semaglutide (NCT06745284) is ongoing with no results yet. MASH fibrosis data, while biopsy-confirmed and statistically significant, comes from a single Phase 2 trial; LIVERAGE Phase 3 replication is required before conclusions can be considered definitive. No peer-reviewed journal publications of the Phase 2 trial results are currently available in the accessible literature; the efficacy and safety data cited throughout this article is drawn from clinical trial registry records and conference presentations rather than published peer-reviewed manuscripts. This is a meaningful limitation in evidence evaluation: registry-reported results have not undergone the same independent peer review process as published journal articles. Publication of the Phase 2 trial data in peer-reviewed journals would strengthen the evidence base considerably.

Is Survodutide Legal? Regulatory & Sports Status

FDA status: Not approved for human use. Survodutide (development code BI 456906) is classified as an investigational new drug under active Phase 3 clinical development by Boehringer Ingelheim. No FDA approval exists for any indication as of July 2026. Regulatory submissions would typically follow completion and analysis of Phase 3 SYNCHRONIZE and LIVERAGE trial results, with Phase 3 primary endpoint data expected no earlier than 2026-2027 for the obesity indications based on available trial timelines.

Research Use Only (RUO): In most jurisdictions, survodutide is classified as an investigational compound and is not approved for human use outside of registered clinical trials. Access is restricted to trial participants enrolled in registered studies. This is not a compound with an established research peptide supply chain comparable to widely available research peptides; it is a pharmaceutical development asset in active clinical development by its sponsoring company.

WADA / USADA status: Survodutide is not currently listed as a prohibited compound on the WADA Prohibited List as of the 2025 prohibited list. However, compounds that produce substantial weight loss and metabolic enhancement may be subject to scrutiny under broader WADA categories such as metabolic modulators under S4, and the regulatory landscape for GLP-1 class agents in sport is evolving. Athletes subject to anti-doping rules should consult the current WADA prohibited list and seek guidance from their national anti-doping organization before considering any compound in this pharmacological class.

Country-specific notes: Because survodutide has not been approved in any jurisdiction, there is no country-specific prescription framework beyond the general classification as an investigational compound. Countries that have approved GLP-1 class agents for obesity and type 2 diabetes have those as separate regulatory pathways; survodutide would require its own independent approval process in each jurisdiction.

Detection: No published detection method for survodutide in anti-doping contexts exists in the available literature as of July 2026. Given the compound's investigational status and the active clinical development program, any detection methodology would be developed within pharmaceutical and anti-doping research contexts as the compound approaches potential approval.

Survodutide vs. Alternatives

Commonly Paired With - Synergistic Stacks

Survodutide is an investigational compound in active Phase 3 trials, and all clinical trials have used it as a standalone agent with diet and exercise counseling. No formal stacking combinations with other peptides or research compounds are documented. Rather than offer speculative pairings that have no evidence basis, the following presents mechanistically reasoned considerations for which combination questions will matter most if survodutide reaches approval.

• Survodutide with supervised resistance training (Mechanistic reasoning; no pharmacological interaction data): Preservation of lean mass during significant weight loss is a documented concern with GLP-1 class agents. Structured resistance training is consistently recommended alongside GLP-1-class pharmacotherapy to minimize muscle mass loss during weight reduction. This is a practical pairing with clear physiological rationale, not a pharmacological combination.
• Survodutide with metformin in T2D (Mechanistic reasoning; class-level evidence from analogous GLP-1 agents): In the type 2 diabetes population, combining GLP-1 receptor agonism with metformin is a well-established pattern across the approved drug class. The complementary mechanisms (GLP-1R-mediated insulin stimulation versus metformin's hepatic glucose suppression) make this a logical pairing, though specific survodutide-plus-metformin interaction data has not been published.
• Survodutide with concurrent insulin dose adjustment (Clinical management consideration; documented in class context): In the T2D population, GLP-1R-mediated insulin stimulation from survodutide may require dose reduction of existing insulin or sulfonylurea therapy to prevent hypoglycemia. This is a combination management consideration documented extensively in the GLP-1 class context.

Note: Because survodutide remains investigational with no established research supply chain, real-world combination protocol data of the kind that exists for more established research peptides does not yet exist for this compound. Evidence grades above reflect the mechanistic and class-level reasoning behind each pairing, not survodutide-specific trial data.

Alternatives - When Another Peptide May Be Considered

Semaglutide (Ozempic / Wegovy) Semaglutide is an approved, commercially available GLP-1 receptor agonist with the strongest evidence base in the weight management class. It lacks the glucagon receptor co-agonism component and therefore does not independently increase energy expenditure through thermogenesis; its weight loss mechanism relies primarily on appetite suppression and gastric emptying delay. For someone seeking a proven, approved, and accessible option now, semaglutide has clinical trial data, regulatory approval, and established supply chains that survodutide does not yet have.

Tirzepatide (Mounjaro / Zepbound) Tirzepatide is an approved dual GIP and GLP-1 receptor agonist, a different dual-receptor strategy than survodutide's GLP-1 and glucagon approach. Both aim to exceed the weight loss achievable with GLP-1-only therapy by adding a second receptor pathway, but the metabolic consequences of GIP versus glucagon co-agonism differ. Tirzepatide does not have the same hepatic fat-clearing mechanism that survodutide's glucagon receptor pathway produces, making survodutide potentially more compelling for MASH specifically. For general obesity, both approaches have demonstrated weight loss exceeding GLP-1 monotherapy, though they have not been compared head to head.

Retatrutide Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, incorporating the same glucagon receptor component as survodutide while adding GIP receptor activity. Phase 2 data for retatrutide showed higher weight loss percentages than dual agonists, though its clinical development is at a similar stage to survodutide. For someone specifically interested in the glucagon receptor pathway, retatrutide and survodutide share that mechanism but differ in additional receptor targets and resulting metabolic profiles.

Comparison table:

Build Your Protocol - MPP CTA

FAQs

What is survodutide?

Survodutide (also spelled survodutide; development code BI 456906) is an investigational acylated synthetic peptide developed by Boehringer Ingelheim, originally licensed from Zealand Pharma. It simultaneously activates two metabolic receptors: the GLP-1 receptor and the glucagon receptor. This dual-agonist design is intended for weight loss, glycemic control, and liver fat reduction. It is currently in Phase 3 clinical trials and has not been approved for human use in any jurisdiction.

What does survodutide do?

Survodutide works through two complementary mechanisms. The GLP-1 receptor side suppresses appetite and stimulates glucose-dependent insulin secretion, while the glucagon receptor side increases resting energy expenditure through thermogenesis and drives fat breakdown in the liver and adipose tissue. In clinical trials, this combination produced dose-dependent body weight reductions of up to 18.7% in Phase 2 obesity trials, meaningful glycemic improvements in type 2 diabetes, and biopsy-confirmed improvements in liver fat and fibrosis in MASH patients.

How long does survodutide take to work?

In Phase 2 obesity trials, the first several weeks of treatment are dominated by the GI adaptation period during dose escalation. Measurable weight reduction becomes clearly apparent from approximately weeks 6-12 onward as dosing stabilizes. Glycemic improvements in the T2D population were measurable at the 16-week mark in Phase 2 data. Liver fibrosis improvement is the slowest outcome: Phase 2 MASH data measured histologic changes at 48 weeks.

What is the typical dose of survodutide?

In Phase 2 trials, survodutide was studied at 0.6 mg, 1.2 mg, 2.4 mg, and 4.8 mg per week for obesity, and up to 6.0 mg per week for MASH. The strongest weight loss signal in Phase 2 appeared at 4.8 mg per week. Survodutide is not commercially available and has no approved dosing; these ranges reflect what clinical trials have studied, not a dosing recommendation for any individual.

Is survodutide legal?

Survodutide is classified as an investigational compound in active Phase 3 clinical development and has not been approved for human use in any jurisdiction as of July 2026. Legal access is limited to participation in registered clinical trials. It is not currently listed on the WADA Prohibited List, though athletes subject to anti-doping rules should verify current status with their national anti-doping organization.

Can survodutide be taken orally?

No. All clinical development of survodutide has been via subcutaneous injection, and no oral formulation has been developed or studied. Like most peptide-class compounds, survodutide would be degraded by gastric acid and digestive enzymes before reaching systemic circulation in any meaningful quantity. The once-weekly injectable format is a deliberate design feature made possible by the compound's acylation modification.

How does survodutide differ from semaglutide?

The primary structural difference is that survodutide activates both the GLP-1 receptor and the glucagon receptor simultaneously, while semaglutide activates only the GLP-1 receptor. The addition of glucagon receptor co-agonism adds a thermogenic mechanism and a hepatic fat-clearing pathway that semaglutide does not have. Phase 2 data described survodutide's weight loss as superior to semaglutide in some analyses, and the liver fat and fibrosis data from survodutide's MASH trial is not matched by semaglutide's evidence base in that indication. Semaglutide has regulatory approval and an established supply chain; survodutide does not.

What makes survodutide different from tirzepatide?

Both are dual-receptor agonists, but they target different receptor pairs. Tirzepatide activates GLP-1 and GIP receptors; survodutide activates GLP-1 and glucagon receptors. The glucagon receptor component in survodutide drives hepatic fat clearance through direct lipolytic signaling in liver tissue, which is the mechanism most relevant to survodutide's MASH and liver fibrosis findings. Tirzepatide does not share this hepatic mechanism in the same way, and the two compounds have not been compared head to head in a published trial.

Why was the Phase 3 dosing schedule changed from Phase 2?

In Phase 2 obesity trials, the dose escalation schedule increased the dose every two weeks, a rapid uptitration that was identified as the primary driver of the high GI adverse event rates (75% of treated participants reported GI events). Phase 3 SYNCHRONIZE trials use a slower uptitration schedule with provisions for temporary dosing pauses, specifically to reduce the GI burden during early treatment while still reaching therapeutic doses. The expectation is that slower escalation will improve tolerability without meaningfully reducing eventual efficacy.

Final Thoughts

Survodutide is not an established research peptide with years of community protocol data and a mature supply chain. It is something different: a carefully engineered investigational drug in active Phase 3 development, built from a genuine mechanistic insight about how the body's own metabolic signaling system works. The dual GLP-1 and glucagon receptor approach captures two distinct pathways toward negative energy balance simultaneously. The clinical data from Phase 2 - particularly the biopsy-confirmed MASH fibrosis improvements and the weight loss magnitudes at the 4.8 mg/week dose - represents some of the most compelling human evidence in the metabolic peptide space. The ongoing Phase 3 program, including the 4,935-participant SYNCHRONIZE-CVOT and the 1,800-patient LIVERAGE trial with its planned 7-year follow-up, will determine whether those Phase 2 signals hold at scale and translate into long-term hard outcomes.

The honest picture is that survodutide carries real uncertainties at this stage. Phase 3 results are not yet available. The GI adverse event burden in Phase 2 was substantial, driven primarily by the rapid dose escalation protocol that Phase 3 has since modified, but still a meaningful tolerability challenge. Treatment discontinuation was approximately 4.5 times more likely than placebo in pooled Phase 2 data. And because survodutide is an active pharmaceutical development asset rather than an established research compound, the sourcing landscape outside of registered clinical trials is neither legitimate nor reliable. Anyone encountering it through informal channels faces quality risks that go beyond what applies to more established research peptides. Regulatory status as an investigational compound means access is not simply a matter of sourcing.

For someone tracking the frontier of metabolic peptide science, the survodutide peptide is worth understanding thoroughly, which is what this guide aims to provide. When Phase 3 data is available and the regulatory picture becomes clearer, the MyPeptidePal platform will be the first place to find personalized protocol guidance informed by both the clinical evidence and real-world experience from tracked protocols. Until then, this guide serves as a reference point for what the science actually shows, presented accurately and without overpromising what an investigational compound at this stage can deliver.

References

1. Boehringer Ingelheim & Zealand Pharma. (2023). A randomised, double-blind, placebo-controlled, dose-finding trial investigating the efficacy and safety of survodutide (BI 456906) in adults with overweight or obesity. ClinicalTrials.gov, NCT04667377.

2. Boehringer Ingelheim. (2022). A randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of survodutide in adults with non-alcoholic steatohepatitis (NASH) and liver fibrosis. ClinicalTrials.gov, NCT05243327.

3. Boehringer Ingelheim. (2022). An open-label trial investigating the pharmacokinetics and tolerability of survodutide in participants with hepatic impairment due to metabolic-associated steatotic liver disease (MASLD). ClinicalTrials.gov, NCT05296733.

4. Boehringer Ingelheim. (2023). SYNCHRONIZE-1: A randomised, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of survodutide in adults with obesity. ClinicalTrials.gov, NCT06066515.

5. Boehringer Ingelheim. (2023). SYNCHRONIZE-2: A randomised, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of survodutide in adults with obesity and type 2 diabetes mellitus. ClinicalTrials.gov, NCT06066528.

6. Boehringer Ingelheim. (2023). SYNCHRONIZE-CVOT: A randomised, double-blind, placebo-controlled trial to investigate the effect of survodutide on major adverse cardiovascular events in adults with overweight or obesity. ClinicalTrials.gov, NCT06077864.

7. Boehringer Ingelheim. (2024). A trial comparing the effects of survodutide and semaglutide on sleeping metabolic rate and fatty acid oxidation. ClinicalTrials.gov, NCT06745284.

Note: All seven references are ClinicalTrials.gov registry entries. No peer-reviewed journal publications of the Phase 2 trial primary results have been identified in the accessible literature as of July 2026. If published journal articles become available for NCT04667377 or NCT05243327, they should be added as citations at the next editorial review cycle. Additional peer-reviewed sources pending editorial review.